Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €4.06 EUR
Change Today +0.095 / 2.40%
Volume 300.0
NNF1 On Other Exchanges
As of 3:44 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

mannkind corp (NNF1) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/30/14 - €9.33
52 Week Low
05/12/15 - €3.11
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for MANNKIND CORP (NNF1)

mannkind corp (NNF1) Details

MannKind Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for diabetes in the United States. Its lead product is AFREZZA inhalation powder, an insulin to control high blood sugar in adult patients with type 1 and type 2 diabetes. MannKind Corporation was founded in 1991 and is headquartered in Valencia, California.

287 Employees
Last Reported Date: 03/2/15
Founded in 1991

mannkind corp (NNF1) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $748.8K
Founder and Executive Chairman
Total Annual Compensation: $858.6K
Chief Financial Officer and Corporate Vice Pr...
Total Annual Compensation: $466.0K
Chief Operating Officer and Corporate Vice Pr...
Total Annual Compensation: $479.2K
Corporate Vice President, General Counsel and...
Total Annual Compensation: $409.2K
Compensation as of Fiscal Year 2014.

mannkind corp (NNF1) Key Developments

MannKind Corporation Appoints James S. Shannon to Board of Directors

MannKind Corporation announced that James S. Shannon, MD, has been elected to the company's board of directors after previously serving as a director from February 2010 until April 2012. The addition of Dr. Shannon brings the total number of MannKind board members to eight.

MannKind Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

MannKind Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, loss from operations was $21.738 million against $41.411 million a year ago. Net loss was $30.658 million or $0.08 per basic and diluted share against $52.056 million or $0.14 per basic and diluted share a year ago. A decline of 47.5% in operating expenses helped improve losses in the quarter.

MannKind Corp. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 12:00 PM

MannKind Corp. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 12:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Matthew J. Pfeffer, Chief Financial Officer and Corporate Vice President.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NNF1:GR €4.06 EUR +0.095

NNF1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NNF1.
View Industry Companies

Industry Analysis


Industry Average

Valuation NNF1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MANNKIND CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at